JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis

  • 0Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Frontiers in Cell and Developmental Biology +

|

April 17, 2025

|

April 17, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Pulmonary fibrosis involves excessive matrix deposition, worsening lung function. This review explores how Sirtuin 3, 6, and 7 (SIRT3, SIRT6, SIRT7) influence lung fibrosis and potential therapeutic strategies.

Area Of Science

  • Pulmonary Medicine
  • Molecular Biology
  • Genetics

Background

  • Pulmonary fibrosis is a progressive lung disease with unknown causes, leading to respiratory failure.
  • The Sirtuin family (SIRT1-7) are NAD+-dependent enzymes regulating cellular processes including fibrosis.
  • Specific roles of SIRT3, SIRT6, and SIRT7 in lung fibrosis remain under-investigated.

Purpose Of The Study

  • To review the molecular mechanisms of SIRT3, SIRT6, and SIRT7 in pulmonary fibrosis.
  • To summarize recent advancements in targeting these sirtuins for fibrosis treatment.

Main Methods

  • Literature review of studies on sirtuins and pulmonary fibrosis.
  • Analysis of molecular pathways involving SIRT3, SIRT6, and SIRT7 in fibrotic processes.

Main Results

  • SIRT3, SIRT6, and SIRT7 play complex roles in regulating extracellular matrix deposition and inflammatory responses in the lung.
  • Emerging research highlights their potential as therapeutic targets for mitigating fibrosis progression.

Conclusions

  • Understanding the specific functions of SIRT3, SIRT6, and SIRT7 is crucial for developing novel anti-fibrotic therapies.
  • Targeting these sirtuins offers a promising avenue for treating pulmonary fibrosis.

Keywords:

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists 01:23

100

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists 01:18

85

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers 01:26

91

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...